Cancer Clinical Trial - Celgene CC-95251-ST-001

CONDITION(S): Colorectal Cancer, Head and Neck (SCCHN), Squamous Cell - TRIAL: Celgene CC-95251-ST-001 - A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Subjects With Advanced Solid and Hematologic Cancers

Study CC-95251-ST-001 is an open-label, Phase 1, dose escalation (Part A) and expansion (Parts B and C), first-in-human clinical study of CC-95251 in subjects with advanced cancers.

Drug

CC-95251; Rituximab; Cetuximab

Trial Type

Interventional

Phase

Phase 1

Condition

Colorectal cancer Head and neck (SCCHN) Squamous cell

Keywords

Colorectal cancer | Head and neck (SCCHN) | Squamous cell